US Research

MED-EL reinvests a significant portion of revenues into the research and development of future technologies. This has been our philosophy since the inception of the MED-EL Company and we’ve consistently done so for more than 20 years. This commitment to further research and development has led to a variety of technological advancements that are now available in marketed products, such as the Fine Structure Processing coding strategy that is currently available in the OPUS processors*.

In order to bring new technologies to the market, a company needs to do the basic research to identify new directions, prove the concept in a pilot study, and eventually complete a clinical trial of the new treatment in human subjects under carefully controlled conditions. The results of a clinical trial are then submitted to the US Food and Drug Administration for approval. Once the new treatment receives FDA approval, it can be made available at any hearing implant center and for any candidates that meet the approved criteria to receive such a device.

Would you like to learn more about US research
and find out if you are a candidate?

> Click here
 for more information
*FSP is not indicated in prelingual children.

© 2017 MED-EL

We are using first- and third-party cookies which enable us to enhance site navigation, analyse site usage, and assist in our marketing efforts. Please click on 'Accept' to agree to the usage of cookies and hide this message permanently. You can find a list and description of the cookies used in our Cookie Policy.